# NCT01572480 (NCT01572480)

> Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01572480
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: National Cancer Institute (NCI)
- Conditions: Multiple Myeloma
- Interventions: Carfilzomib; Revlimid; Dexamethasone
- Enrollment: 55
- Primary outcome: Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria

## Commentary we found

- X threads: 6

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct01572480